Latest:
Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer
Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jennifer L. Redmond, DrPH
Latest:
Tackling Patient Recruitment Challenges in Clinical Trials
Patients fear being a "guinea pig" or receiving a placebo, healthcare providers do not have time to keep up with all of the clinical trial information or talk with patients in depth, conducting clinical trials is very expensive for healthcare systems, and funding continues to decline for research.
Jennifer Ligibel, MD
Latest:
Dr. Ligibel Discusses Lifestyle Intervention in Breast Cancer
Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses lifestyle intervention in the treatment of patients with breast cancer.
Jennifer Logan, MD, MPH
Latest:
Opening the Door for Novel Therapies in Triple-Negative Breast Cancer
During a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.
Jennifer L.W. Fink
Latest:
Microbiome Emerges as a Hot Topic in Cancer Research
Researchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.
Jennifer M. Kapo, MD
Latest:
Dr. Kapo on Addressing Palliative Care With Patients
Jennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.
Jennifer N. Brudno, MD
Latest:
Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell Malignancies
Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
Jennifer R. Brown, MD, PhD
Latest:
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jennifer R. Brown, MD, PhD, Dana Farber Cancer Institute
Latest:
Rapid Readouts: First interim analysis of the ALPINE study: a phase III randomized trial of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Jennifer R. Brown, MD, PhD presents an interim analysis from the ALPINE study of zanubrutinib vs. ibrutinib in patients with R/R CLL/SLL presented at the 2021 European Hematology Association virtual congress.
Jennifer R. Green, MD
Latest:
Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia
Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.
Jennifer Shepphird, PhD
Latest:
Trials Show Efficacy of PARP-Targeted Agent in Prostate Cancer
Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.
Jennifer Temel, MD
Latest:
Dr. Temel on Anorexia and Cachexia in NSCLC
Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School
Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and
Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.
Jennifer Woyach, MD
Latest:
Dr Woyach on Responses to Pirtobrutinib in CLL/SLL With/Without Prior BCL2 Inhibitor Exposure
Jennifer A Woyach, MD, discusses the efficacy of pirtobrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who progressed on treatment with a covalent BTK inhibitor, including subgroups with or without previous exposure to a BCL2 inhibitor.